Equities Analysts Set Expectations for MLTX Q1 Earnings

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for MoonLake Immunotherapeutics to ($0.98) from ($0.86), while keeping a Buy rating and a $45 price target.
• MoonLake reported its latest quarterly results with EPS of ($0.98), missing the consensus estimate of ($0.91) by $0.07.
• Analyst sentiment remains mixed overall: the stock has nine Buy ratings, four Hold ratings, and three Sell ratings, with a consensus Hold and an average price target of $23.85.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2026 earnings estimates for MoonLake Immunotherapeutics in a research report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.98) for the quarter, down from their previous forecast of ($0.86). HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q2 2026 earnings at ($0.81) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($3.25) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at $0.90 EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($3.06) EPS.

Several other brokerages also recently weighed in on MLTX. Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and upped their target price for the stock from $12.00 to $40.00 in a report on Thursday, March 19th. Needham & Company LLC upped their price objective on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday. Royal Bank Of Canada increased their target price on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a "sector perform" rating in a research report on Monday, March 2nd. Oppenheimer boosted their price target on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Tuesday, February 24th. Finally, Wolfe Research upgraded MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and upped their price target for the stock from $12.00 to $24.00 in a research note on Monday, March 23rd. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $23.85.

MoonLake Immunotherapeutics Trading Down 3.5%

NASDAQ:MLTX opened at $18.19 on Wednesday. The company has a 50 day simple moving average of $17.49 and a two-hundred day simple moving average of $15.37. The company has a market cap of $1.30 billion, a PE ratio of -4.70 and a beta of 1.01. The company has a current ratio of 9.27, a quick ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.07).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new position in MoonLake Immunotherapeutics in the fourth quarter valued at about $26,000. FNY Investment Advisers LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at about $28,000. Bank of America Corp DE boosted its holdings in shares of MoonLake Immunotherapeutics by 64.7% in the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company's stock valued at $32,000 after buying an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company's stock worth $42,000 after buying an additional 3,166 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock worth $45,000 after buying an additional 1,069 shares during the last quarter. 93.85% of the stock is owned by institutional investors.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total value of $62,962,500.00. Following the transaction, the director owned 1,039,238 shares of the company's stock, valued at $17,448,806.02. This represents a 78.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Da Silva Jorge Santos sold 51,873 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $18.23, for a total transaction of $945,644.79. Following the transaction, the chief executive officer directly owned 2,924,893 shares in the company, valued at approximately $53,320,799.39. The trade was a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,900,000 shares of company stock worth $65,714,663. Insiders own 12.05% of the company's stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.